AvaBridge ELISA     For Avastin Biosimilar Comparison 

Complete kit for the systematic 3-D conformational comparability analysis of 

Avastin biosimilar molecule to Bevacizumab (Avastin trade name).

Bevacizumab is a humanized monoclonal antibody, produced by Genentech, that inhibits vascular

endothelial growth factor A (VEGF-A). VEGF-A is a chemical signal that stimulates angiogenesis in a 

variety of diseases, especially in cancer. Bevacizumab was the first clinically available angiogenesis 

inhibitor in the United States and was approved by the U.S. Food and Drug Administration (FDA) 

for certain metastatic cancers. It received its first approval in 2004 for combination use with standard 

chemotherapy for metastatic colon cancer. 

This kit will allow for conformational comparison between Avastin Biosimilars and authentic Bevacizumab.  

AB000201        AvaBridge ELISA (for Avastin Biosimilar Comparison)        1 Kit 

☞   Click here for detailed product instruction

☞   Click here for AvaBridge MSDS